Advaxis inks pact with Incyte to test cervical cancer vaccine combo

Advaxis ($ADXS), on a partnering spree after joining with Merck ($MRK) and AstraZeneca ($AZN) to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte ($INCY) to trial one of its prospects in cervical cancer. Under the deal, the two will split costs of a Phase II study testing Advaxis' ADXS-HPV and Incyte's epacadostat (formerly INCB24360). The pair plans to get started later this year, using results to determine whether the tandem should move into Phase III. Release | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.